HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $8 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and maintains $8 price target.
Stocks · News reference
Milestone Pharmaceuticals Announces First Patient Enrolled In Phase 3 Trial Of Etripamil In Approximately 150 Patients With Atrial Fibrillation With Rapid Ventricular Rate
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Milestone Pharmaceuticals Says China’s National Medical Products Administration Approves Etripamil Nasal Spray For Treatment Of Paroxysmal Supraventricular Tachycardia In Adults
Milestone Pharmaceuticals Presenting Data In Moderated EPoster Session Titled 'he Impact of PSVT on Patients’ Daily Life and QoL in Between Episodes' At European Society Of Cardiology Congress 2026
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced findings from a longitudinal study